Patent US5179093A successfully refreshed from Google Patents.
US5179093A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Quinoline-diones
Assignee: Merck Sharp & Dohme LLC
•
Filing: 1991-05-10
•
Granted: 1993-01-12
•
Expires: 2011-05-10
Abstract
Abstract Compounds of the formula <IMAGE> I or a pharmaceutically acceptable salt thereof wherein, R is H, halogen, (C1-C6) alkyl, N(C1-C6 alkyl/aryl)2, OH, O-(C1-C6) alkyl/aryl, CH2OH, COOH, COO-alkyl/aryl, SO2NH2, or SO2NH (C1-C6 alkyl/aryl); R1 is C1-C6 alkyl, cycloalkyl, C2-C6 alkenyl, heteroaryl, substituted heteroaryl, heterocycloalkyl, -CH2-aryl, -CH2-substituted aryl, -CH2-heteroaryl, or -CH2-substituted heteroaryl; R2 is H, C1-C6 alkyl or aryl; <IMAGE> is an aromatic ring or a heteroaromatic ring; and X is O or N-(alkyl/aryl/alkyl-aryl/alkoxylalkoxyaryl) are described. These compounds are useful as agents for treating viruses.
Inventors
- 👤 Adriano Afonso
- 👤 Stuart W. McCombie
- 👤 Jay Weinstein
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 18:31
CPC Classifications
C; C07; C07D; C07D215/00; C07D215/02; C07D215/16; C07D215/20; C07D215/22; C07D401/00; C07D401/02; C07D401/12
Claims Analysis
Total Claims: 15
Claim 1
Independent Claim
107 words
A compound of the formula ##STR71## or a pharmaceutically acceptable salt thereof wherein, R is H, halogen, (C 1 -C 6 ) alkyl, N(C 1 -C 6 alkyl) 2 , OH, O--(C 1 -C 6 ) alkyl, CH 2 OH, COOH, COO-alkyl, SO 2 NH 2 or SO 2 NH (C 1 -C 6 alkyl); R 1 is C 1 -C 6 alkyl, ##STR72## adamantyl, C 2 -C 6 alkenyl, --CH 2 -phenyl, --CH 2 -pyridyl ##STR73## R 2 is H,or C 1 -C 6 alkyl; ##STR74## is phenyl, or X is N-C 1 -C 8 alkyl or phenyl (C 1 -C 6 ) alkyl or ##STR75##
Claim 2
Dependent Claim
107 words
A compound of the formula ##STR71## or a pharmaceutically acceptable salt thereof wherein, R is H, halogen, (C 1 -C 6 ) alkyl, N(C 1 -C 6 alkyl) 2 , OH, O--(C 1 -C 6 ) alkyl, CH 2 OH, COOH, COO-alkyl, SO 2 NH 2 or SO 2 NH (C 1 -C 6 alkyl); R 1 is C 1 -C 6 alkyl, ##STR72## adamantyl, C 2 -C 6 alkenyl, --CH 2 -phenyl, --CH 2 -pyridyl ##STR73## R 2 is H,or C 1 -C 6 alkyl; ##STR74## is phenyl, or X is N-C 1 -C 8 alkyl or phenyl (C 1 -C 6 ) alkyl or ##STR75##
Claim 3
Dependent Claim
19 words
A compound according to claim 1 wherein X is selected from the group consisting of N-benzyl, N-hexyl, and N-heptyl.
Claim 4
Dependent Claim
10 words
A compound according to claim 1, wherein ##STR76## is phenyl.
Claim 5
Dependent Claim
11 words
A compound according to claim 1 wherein R 2 is H.
Claim 6
Dependent Claim
21 words
A compound according to claim 1 wherein R 1 is selected from the group consisting of benzyl and --CH 2 -pyridyl.
Claim 7
Dependent Claim
17 words
A compound according to claim 1 wherein R is H, halogen, or C 1 -C 6 alkyl.
Claim 8
Dependent Claim
32 words
A compound according to claim 1 wherein ##STR77## is an aromatic ring, R is H, Cl, or methyl, R 2 is H, and R 1 is benzyl or --CH 2 -pyridyl. pyridyl.
Claim 9
Dependent Claim
15 words
A compound, selected from the group consisting of: ##STR78## or a pharmaceutically acceptable salt thereof.
Claim 10
Dependent Claim
15 words
A compound, selected from the group consisting of: ##STR78## or a pharmaceutically acceptable salt thereof.
Claim 11
Dependent Claim
19 words
A compound according to claim 8, selected from the group consisting of: ##STR79## or a pharmaceutically acceptable salt thereof.
Claim 12
Dependent Claim
9 words
A compound; ##STR80## or a pharmaceutically acceptable salt thereof.
Claim 13
Dependent Claim
9 words
A compound; ##STR80## or a pharmaceutically acceptable salt thereof.
Claim 14
Dependent Claim
25 words
A pharmaceutical composition comprising an anti-herpes group virus effective amount of a compound as defined in claim 1 in combination with a pharmaceutically acceptable carrier.
Claim 15
Dependent Claim
35 words
A method for treating anti-herpes group viral infections in a mammal which comprises administering to a mammal in need of such treatment an anti-herpes group virally effective amount of a compound according to claim 1.
References Cited (Backward Citations)
US3025299A
Cited
US3132140A
Cited
US3449335A
Cited
US3715360A
Cited
US3960868A
Cited
US3962445A
Cited
US4190659A
Cited
US4006237A
Cited
US4031099A
Cited
US4022770A
Cited
US4107310A
Cited
US4124587A
Cited
US4168312A
Cited
US4187309A
Cited
EP0093251A2
Cited
US4607039A
Cited
US4526894A
Cited
US4902693A
Cited
JPS63295561A
Cited
DD269382A1
Cited
JPH02152966A
Cited
EP0385630A2
Cited
US4959363A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1996-01-12 | 1996-07-13 | 1997-01-12 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2000-01-12 | 2000-07-13 | 2001-01-12 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2004-01-12 | 2004-07-13 | 2005-01-12 | $7700.00 | Window Closed / Lapsed |